LLY : Analysis & Opinions

  1. Blockbuster Potential of Migraine Drugs (AMGN, ALDR)

    Drug makers who launch migraine biologic drugs are expected to benefit from blockbuster sales.
  2. LLY Up on Positive European Ad Comm Review

    A rheumatoid arthritis drug has received a positive opinion from the EMEA.
  3. Eli Lilly & Co. Surges on Strong FY'17 Guidance (LLY)

    Shares of the pharmaceutical company are spiking higher today after providing 2017 guidance that was ahead of expectations.
  4. Eli Lilly Boosts Dividend 2%, Despite Recent Woes

    The has not been a banner year for  Eli Lilly (NYSE: LLY). Nevertheless, the pharmaceutical giant just enacted a fresh dividend ...
  5. Lilly Shares Spike On Jardiance Approval (LLY)

    Shares of Eli Lilly & Co (LLY) are spiking after the FDA approved and expanded the label for Jardiance.
  6. Drugmakers' Price Duopoly (PFE, LLY)

    Legislators are becoming more and more concerned that many big drugmakers are boosting prices in tandem.
  7. Does Lilly's Alzheimer's Fail Hurt Biogen? (BIIB)

    The failure of Eli Lilly's Alzheimer's drug study may or may not hurt rival drug makers that are developing similar dementia ...
  8. Eli Lilly Tanks on Alzheimer's Drug Failure (LLY)

    Eli Lilly will not seek US approval for its Alzheimer's drug solanezumab after it failed in a late-stage study.
  9. Eli Lilly's Drug Solanezumab Failed In A Key Alzheimer's Disease Trial (LLY, BIIB)

    Eli Lilly & Co. reported that topline results for its phase III trial for Solanezumab, a monoclonal antibody, failed ...
  10. Bernie Sanders Slams Drug Price Fixing (LLY, SNY)

    Senator Bernie Sanders is asking the DOJ and the FTC to investigate insulin drug makers for alleged price fixing.
  11. Eli Lilly Poised For an Era of Rapid Growth (LLY)

    Goldman Sachs recently upgraded Eli Lilly from neutral to buy, citing a large late-stage pipeline as catalyst for a high ...
  12. Eli Lilly President/CEO to Retire at Year's End

    This will be the final year of Eli Lilly (NYSE: LLY) President and CEO John Lechleiter's tenure. The company has announced ...
  13. (ADHD) Who are Alcobra's Main Competitors?

    Learn about Alcobra, a young player in treating attention deficit hyperactiviy disorder (ADHD) that may give its competitors ...
  14. Eli Lilly Stock Surge Ahead of Earnings (LLY)

    As analysts increased the company's profit forecasts, LLY stock responded favorably. But there's not much room left for multiple ...
  15. Valeant vs. Abbott Labs: Which Is Better for My Portfolio? (VRX, ABT)

    Explore the differences between Abbott Laboratories and Valeant Pharmaceuticals, as well as which stock is the best addition ...
  16. 3 Best Dividend-Paying U.S. Health Care Mutual Funds (VGHCX, BMY)

    Find out which mutual funds are paying the highest dividend yields in the health care sector, which has underperformed all ...
  17. How Sanofi Makes Money (SNY)

    Sanofi, a French pharmaceutical firm, is the name behind some of the drugs you use every day. Here's how it operates.
  18. Top 5 Dividend Stocks for a Market Sell-off

    Finding the right dividend stocks for bear markets isn't about seeking the highest yield. Instead, consider these five fiscally-solid ...
  19. How Novartis Makes Money

    A look at the unparalleled growth of the world's biggest pharmaceutical company: Novartis AG.
  20. Is Eli Lilly Now a Solid Income Investor Play?

    Pharmaceutical giant Eli Lilly (NYSE: LLY) has declared a fresh dividend raise, albeit an incremental one. The company has ...
  21. How Eli Lilly Makes its Money

    Drugs mean big profits in America. Here's how the country's oldest pharmaceutical firm keeps its toehold in the market.
  22. Biogen Earnings Preview: 3 Key Factors to Monitor (BIIB, LLY)

    For the better part of a decade, Biogen (NASDAQ: BIIB) could simply do no wrong by its shareholders. Whereas the S&P ...
  23. Why There's Far More To Pfizer Than Viagra

    Pfizer, Inc. is one of the world's largest and most profitable pharmaceutical companies, and not just because of that little ...
  24. Novo Nordisk Getting Its Trial By Fire

    Novo Nordisk is facing more challenges than it has in a while, but the growth remains strong.
  25. Investing For The Global Diabetes Epidemic

    Sadly, diabetes is quickly becoming a global epidemic. Within these grim statistics, investors can find opportunities with ...
  26. 10 Drug Stocks for Safety and Yields

    Big pharma is an attractive destination for traders and investors looking for safety, yields, and solid value in the current ...
  27. Novo Nordisk Still One Of The Best Around

    Novo Nordisk is one of the best pharmaceutical companies in the world - and it's priced accordingly.
  28. Top 3 Sectors For Value Investors

    As the U.S. economy has recovered, so have the equity markets. Learn the best-value sectors that investors should focus on. ...